Enliven Therapeutics (ELVN) Jefferies Global Healthcare Conference 2026 summary

Company overview and lead asset

• Focuses on developing novel small molecules with improved specificity and safety over existing drugs targeting known biology.

• Lead asset is a BCR-ABL1 TKI for CML, showing high specificity and limited off-target toxicity.

• Significant phase I data generated, with an updated dataset to be presented at EHA.

Clinical data and expectations

• Updated phase I data cut in March includes additional patients and longer follow-up, especially at the 80 mg QD dose intended for phase III.

• Efficacy evaluable population will increase by 5-15 patients, with most new data from maturing cohorts and the recommended phase III dose.

• Data will be presented at EHA on June 11, with a pre-market call scheduled.

Efficacy interpretation and benchmarking

• Achieved MMR rates are influenced by data maturity and patient selection; early data can be inflated by censoring non-responders.

• Mature 80 mg data showed 38% MMR, while less mature 60/120 mg cohorts showed 53%; no dose response expected between 60 and 120 mg.

• Study population is heavily pre-treated and more resistant than other phase I CML studies.

• Comparisons to TERN-701 and SCEMBLIX must consider differences in patient selection and data maturity.

• Targeting to be at least as competitive as asciminib (SCEMBLIX) in third line (approx. 30% MMR) and ideally higher, especially given the challenging patient population.